12 Health Care Stocks Moving In Thursday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Thursday's after-market session, several healthcare stocks experienced significant movements. Dermata Therapeutics (DRMA) saw a substantial increase of 113.1%, while Applied Therapeutics (APLT) faced a sharp decline of 36.9%. Other notable gainers include Intelligent Bio Solutions (INBS), Exagen (XGN), Nemaura Medical (NMRD), Inspire Veterinary (IVP), and MyMD Pharmaceuticals (MYMD). Conversely, Voyager Therapeutics (VYGR), Avenue Therapeutics (ATXI), Alaunos Therapeutics (TCRT), Cognition Therapeutics (CGTX), and Allogene Therapeutics (ALLO) were among the losers.
January 04, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Dermata Therapeutics stock surged by 113.1% to $1.3, with a market value of outstanding shares at $4.6 million.
The significant surge in DRMA's stock price indicates strong investor interest, which could lead to continued momentum in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Intelligent Bio Solutions shares rose by 19.17% to $0.36, with a market value of outstanding shares at $3.1 million.
The increase in INBS's stock price may attract more attention from investors, potentially leading to further short-term gains.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Inspire Veterinary shares rose by 9.85% to $0.38, with a market value of outstanding shares at $3.3 million.
Inspire Veterinary's stock price gain could suggest growing investor interest, potentially leading to more short-term increases.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
MyMD Pharmaceuticals stock went up by 9.52% to $0.23, with a market value of outstanding shares at $11.7 million.
The increase in MYMD's stock price may be a sign of positive momentum, which could continue in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Nemaura Medical shares increased by 12.53% to $0.12, with a market value of outstanding shares at $3.4 million.
The rise in NMRD's stock price could indicate a positive trend, possibly leading to more short-term gains.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Exagen shares climbed by 15.33% to $2.18, with a market value of outstanding shares at $37.1 million.
Exagen's stock price increase reflects positive investor sentiment, which could contribute to further short-term appreciation.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Allogene Therapeutics stock went down by 6.49% to $3.17, with a market value of outstanding shares at $533.4 million.
Allogene Therapeutics' stock price decline could be a sign of investor concern, potentially leading to more short-term selling pressure.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Applied Therapeutics stock plummeted by 36.9% to $2.39, with a market value of outstanding shares at $184.5 million.
The sharp decline in APLT's stock price suggests a negative investor sentiment, which could lead to further short-term downside.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Avenue Therapeutics stock decreased by 9.59% to $0.31, with a market value of outstanding shares at $4.1 million.
The decline in ATXI's stock price suggests negative market sentiment, which may continue to affect the stock in the short term.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Cognition Therapeutics stock dropped by 6.99% to $1.85, with a market value of outstanding shares at $59.4 million.
The decrease in CGTX's stock price may reflect investor skepticism, which could lead to further short-term negative performance.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Alaunos Therapeutics shares fell by 7.72% to $0.12, with a market cap of $28.2 million.
Alaunos Therapeutics' stock price decline could indicate a bearish outlook, possibly leading to further short-term drops.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Voyager Therapeutics stock declined by 10.07% to $9.74, with a market cap of $428.5 million.
Voyager Therapeutics' stock price drop could reflect investor concerns, potentially leading to further short-term declines.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80